Syngene Chief: Large Cap Biopharma Taking China 'Rotation' More Seriously

 
• By Anju Ghangurde

A material shift in China derisking discussions by big biopharma against the backdrop of the proposed US BIOSECURE Bill is seen presenting opportunities for Syngene, though the tight US biotech funding environment dampened demand for the Indian CRDMO’s R&D services in Q4.

Pharma looks at China plus one options • Source: Shutterstock

More from Business

More from Scrip